BRCA1 Antibody (OAAF01252)

Catalog No: OAAF01252 (Formerly GWB-ASC640)

Size:100 ug

Western blot analysis of extracts from COLO205/HepG2 cells, treated with serum 20% 15', using BRCA1 Antibody. The lane on the right is treated with the synthesized peptide.

Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using BRCA1 Antibody. The picture on the right is treated with the synthesized peptide.

Product Info

• Predicted Species Reactivity: Human|Mouse|Rat
• Product Format: Liquid
• Clonality: Polyclonal
• Host: Rabbit
• Application: Enzyme-linked immunosorbent assay|Immunofluorescence|Immunohistochemistry|Immunohistochemistry-Paraffin|Western blot
• Reconstitution and Storage: -20°C
• Immunogen: The antiserum was produced against synthesized peptide derived from human BRCA1.
• Purification: The antibody was purified from rabbit antiserum by affinity-chromatography using immunogen.
• Specificity: BRCA1 antibody detects endogenous levels of total BRCA1 protein.
• Formulation: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Dilution: The optimal working dilution should be determined by the end user.
• Application Info: WB: 1:500~1:1000; IHC: 1:50~1:100; ELISA: 1:20000
• Reference: Miki Y., Science 266:66-71(1994).
  Smith T.M., Genome Res. 6:1029-1049(1996).
  Wilson C.A., Oncogene 14:1-16(1997).

Target Info

• Gene Symbol: BRCA1
• Gene Full Name: BRCA1 DNA repair associated
• Alias Symbols: BRCA1/BRCA2-containing complex, subunit 1;BRCAI;BRCC1;breast and ovarian cancer susceptibility protein 1;breast cancer 1, early onset;breast cancer type 1 susceptibility protein;BROVCA1;early onset breast cancer 1;Fanconi anemia, complementation group S;FANCS;IRIS;PNCA4;PPP1R53;protein phosphatase 1, regulatory subunit 53;PSCP;RING finger protein 53;RING-type E3 ubiquitin transferase BRCA1;RNF53.
• NCBI Gene Id: 672
• Protein Name: Breast cancer type 1 susceptibility protein
• Description of Target: E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8. Acts as a transcriptional activator (PubMed:20160719).
• Uniprot ID: P38398
• Protein Accession #: NP_009225.1
• Molecular Weight: 207 kDa